Djoeke de Wit

Everolimus in patients with advanced follicular-derived thyroid cancer; results of a phase II clinical trial.

T Schneider, Djoeke de Wit, Thera P. Links et al. · The Journal of Clinical Endocrinology & Metabolism · 2016 · 90 citations · Full text

Medicine, Oncology, Pharmacology +17

A validated assay for the simultaneous quantification of six tyrosine kinase inhibitors and two active metabolites in human serum using liquid chromatography coupled with tandem mass spectrometry

Nielka P. van Erp, Djoeke de Wit, Henk‐Jan Guchelaar et al. · Journal of Chromatography B · 2013 · 85 citations

Medicine, Pharmaceutical Analysis, Pharmacology +17

Therapeutic Drug Monitoring to Individualize the Dosing of Pazopanib

Djoeke de Wit, Nielka P. van Erp, Jan den Hartigh et al. · Therapeutic Drug Monitoring · 2014 · 57 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +15

Everolimus pharmacokinetics and its exposure–toxicity relationship in patients with thyroid cancer

Djoeke de Wit, T Schneider, Dirk Jan A. R. Moes et al. · Cancer Chemotherapy and Pharmacology · 2016 · 52 citations · Full text

Medicine, Oncology, Pharmacology +15

Beneficial Effects of the mTOR Inhibitor Everolimus in Patients with Advanced Medullary Thyroid Carcinoma: Subgroup Results of a Phase II Trial

T Schneider, Djoeke de Wit, Th. P. Links et al. · International Journal of Endocrinology · 2015 · 48 citations · Full text

Medicine, Oncology, Pharmacology +17